Science – Page 69

SCOTUS mifepristone case: Justices focus on anti-abortion groups’ legal standing

Abortion, alito, barrett, clarence thomas, comstock, drug approval, fda, gorsuch, kagan, ketanji brown jackson, medication abortion, mifepristone, Policy, Science, SCOTUS / Paul Patrick / March 26, 2024

Demonstrators participate in an abortion-rights rally outside the Supreme Court as the justices of the court hear oral arguments in the case of the <em>US Food and Drug Administration v. Alliance for Hippocratic Medicine</em> on March 26, 2024 in Washington, DC.” src=”https://cdn.arstechnica.net/wp-content/uploads/2024/03/GettyImages-2115237711-800×533.jpeg”></img><figcaption>
<p><a data-height=

The US Supreme Court on Tuesday heard arguments in a case seeking to limit access to the abortion and miscarriage drug mifepristone, with a majority of justices expressing skepticism that the anti-abortion groups that brought the case have the legal standing to do so.

The case threatens to dramatically alter access to a drug that has been safely used for decades and, according to the Guttmacher Institute, was used in 63 percent of abortions documented in the health care system in 2023. But, it also has sweeping implications for the Food and Drug Administration’s authority over drugs, marking the first time that courts have second-guessed the agency’s expert scientific analysis and moved to restrict access to an FDA-approved drug.

As such, the case has rattled health experts, reproductive health care advocates, the FDA, and the pharmaceutical industry alike. But, based on the line of questioning in today’s oral arguments, they have reason to breathe a sigh of relief.

Standing

The case was initially filed in 2022 by a group of anti-abortion organizations led by the Alliance for Hippocratic Medicine. They collectively claimed that the FDA’s approval of mifepristone in 2000 was unlawful, as were FDA actions in 2016 and 2021 that eased access to the drug, allowing for it to be prescribed via telemedicine and dispensed through the mail. The anti-abortion groups justified bringing the lawsuit by claiming that the doctors in their ranks are harmed by the FDA’s actions because they are forced to treat girls and women seeking emergency medical care after taking mifepristone and experiencing complications.

The FDA and numerous medical organizations have emphatically noted that mifepristone is extremely safe and the complications the lawsuit references are exceedingly rare. Serious side effects occur in less than 1 percent of patients, and major adverse events, including infection, blood loss, or hospitalization, occur in less than 0.3 percent, according to the American College of Obstetricians and Gynecologists. Deaths are almost non-existent.

Still, a conservative federal judge in Texas sided with the anti-abortion groups last year, revoking the FDA’s 2000 approval. A conservative panel of judges for the Court of Appeals for the 5th Circuit in New Orleans then partially overturned the ruling, undoing the lower court’s ruling on the 2000 approval, allowing the FDA’s approval to stand, but still finding the FDA’s 2016 and 2021 actions unlawful. The ruling was frozen until the Supreme Court weighed in.

Today, many of the Supreme Court Justices went back to the very beginning: the claimed scenario that the plaintiff doctors have been or will imminently be harmed by the FDA’s actions. At the outset of the hearings, Solicitor General Elizabeth Prelogar argued that the plaintiffs had not been harmed, and, even if they were, they already had federal protections and recourse. Any doctor who consciously objects to caring for a patient who has had an abortion already has federal protections that prevent them from being forced to provide that care, Prelogar argued. As such, hospitals have legal obligations and have set up contingency and staffing plans to prevent violating those doctors’ federal conscious objection protections.

SCOTUS mifepristone case: Justices focus on anti-abortion groups’ legal standing Read More »

Bridge collapses put transportation agencies’ emergency plans to the test

Baltimore, bridges, Cargo ship, Science, syndication, transportation / Paul Patrick / March 26, 2024

Enlarge / The Dali container vessel after striking the Francis Scott Key Bridge that collapsed into the Patapsco River in Baltimore on March 26. The commuter bridge collapsed after being struck by a container ship, causing vehicles to plunge into the water and halting shipping traffic at one of the most important ports on the US East Coast.

A container ship rammed into the Francis Scott Key Bridge in Baltimore around 1: 30 am on March 26, 2024, causing a portion of the bridge to collapse into Baltimore Harbor. Officials called the event a mass casualty and were searching for people in the waters of the busy port.

This event occurred less than a year after a portion of Interstate 95 collapsed in north Philadelphia during a truck fire. That disaster was initially expected to snarl traffic for months, but a temporary six-lane roadway was constructed in 12 days to serve motorists while a permanent overpass was rebuilt.

US cities often face similar challenges when routine wear and tear, natural disasters, or major accidents damage roads and bridges. Transportation engineer Lee D. Han explains how planners, transit agencies, and city governments anticipate and manage these disruptions.

How do agencies plan for disruptions like this?

Planning is a central mission for state and metropolitan transportation agencies.

Traditional long-term planning focuses on anticipating and preparing for growing and shifting transportation demand patterns. These changes are driven by regional and national economic and population trends.

Shorter-term planning is about ensuring mobility and safety during service disruptions. These disruption events can include construction, major scheduled events like music festivals, traffic incidents such as crashes and hazardous material spills, emergency evacuations, and events like the bridge collapse in Baltimore.

Agencies have limited resources, so they typically set priorities based on how likely a given scenario is, its potential adverse effects, and the countermeasures that officials have available.

For bridges, the Federal Highway Administration sets standards and requires states to carry out periodic inspections. In addition, agencies develop a detouring plan for each bridge in case of a structural failure or service disruption. In Baltimore, Key Bridge traffic will be routed through two tunnels that pass under the harbor, but trucks carrying hazardous materials will have to take longer detours.

Major bridges, such as those at Mississippi River crossings, are crucial to the nation’s economy and security. They require significant planning, commitment, and coordination between multiple agencies. There usually are multiple contingency plans in place to deal with immediate traffic control, incident response, and field operations during longer-term bridge repair or reconstruction projects.

What are some major challenges of rerouting traffic?

Bridges are potential choke points in highway networks. When a bridge fails, traffic immediately stops and begins to flow elsewhere, even without a formal detouring plan. Transportation agencies need to build or find excess capacity before a bridge fails so that the disrupted traffic has alternative routes.

This is usually manageable in major urban areas that have many parallel routes and bridges and built-in redundancy in their road networks. But for rural areas, failure of a major bridge can mean extra hours or even days of travel.

When traffic has to be rerouted off an interstate highway, it can cause safety and access problems. If large trucks are diverted to local streets that were not designed for such vehicles, they may get stuck on railroad tracks or in spaces too small for them to turn around. Heavy trucks can damage roads and bridges with low weight limits, and tall trucks may be too large to fit through low-clearance underpasses.

Successful rerouting requires a lot of coordination between agencies and jurisdictions. They may have to adjust road signal timing to deal with extra cars and changed traffic patterns. Local drivers may need to be directed away from these alternative routes to prevent major congestion.

It’s also important to communicate with navigation apps like Google Maps and Waze, which every driver has access to. Route choices that speed up individual trips may cause serious congestion if everyone decides to take the same alternate route and it doesn’t have enough capacity to handle the extra traffic.

Bridge collapses put transportation agencies’ emergency plans to the test Read More »

Workers with job flexibility and security have better mental health

absenteeism, anxiety, health, job flexibility, job security, Mental Health, psychological distress, return-to-office, Science / Kris Guyer / March 25, 2024

Healthier work —

Job flexibility and security were linked to significantly less psychological distress and anxiety.

Beth Mole – Mar 25, 2024 10: 17 pm UTC

American workers who have more flexibility and security in their jobs also have better mental health, according to a study of 2021 survey data from over 18,000 nationally representative working Americans.

The study, published Monday in JAMA Network Open, may not be surprising to those who have faced return-to-office mandates and rounds of layoffs amid the pandemic. But, it offers clear data on just how important job flexibility and security are to the health and well-being of workers.

For the study, job flexibility was assessed in terms of ease of adjusting work schedules, advance notice of scheduling changes, and whether schedules were changed by employers often. People who reported greater flexibility in their job had 26 percent lower odds of serious psychological distress, which was measured on a validated, widely used questionnaire that assesses depression, nervousness, hopelessness, and worthlessness, among other forms of distress. Greater job flexibility was also linked to 13 percent lower odds of experiencing daily anxiety, 11 percent lower odds of experiencing weekly anxiety, and 9 percent lower odds of experiencing anxiety a few times a year.

Job security also appeared to be a boon for mental health. Workers were asked how likely they thought that they may lose their job or get laid off in the next 12 months. Those who reported feeling more secure in their positions had 25 percent lower odds of serious psychological distress. Job security was also associated with 27 percent lower odds of experiencing daily anxiety and 21 percent lower odds of experiencing weekly anxiety.

The study, led by Monica Wang of Boston University’s School of Public Health, also looked at how job flexibility and security affected job absenteeism, finding mixed results. Both job flexibility and security were linked to fewer days where workers reported working while they were sick—suggesting that flexibility and security enabled workers to make use of sick leave when they needed it. In line with that finding, more job flexibility led to more days where workers reported being absent due to illness in the three months prior to the survey. Greater job security, on the other hand, led to fewer absences over the previous three and 12 months.

It’s unclear why that would be the case, but the researchers speculated that “Job security may lead to lower work absenteeism due to higher work satisfaction, decreased job-related stress, and financial security,” they wrote.

Overall, the study’s findings indicate “the substantive impact that flexible and secure jobs can have on mental health in the short-term and long-term,” the researchers conclude.

They do note limitations of the study, the main one being that the study identifies associations and can’t determine that job flexibility and security directly caused mental health outcomes and the work absence findings. Still, they suggest that workplace policies could improve the mental health of employees. This includes flexible scheduling, leave policies, and working arrangements, including remote and hybrid options, which can all allow workers to accommodate personal and family needs. For improving job security, the researchers recommend longer-term contracts and long-term strategies to invest in employees, such as “uptraining,” skill development, and advancement opportunities.

Workers with job flexibility and security have better mental health Read More »

Eternal Sunshine of the Spotless Mind and the philosophy of self, identity, and memory

cognitive neuroscience, Eternal Sunshine of the Spotless Mind, films, memory, personal identity, Science, science of memory, science philosophy / Kris Guyer / March 25, 2024

<em>Eternal Sunshine of the Spotless Mind</em> stars Jim Carrey in one of his most powerful dramatic roles.” src=”https://cdn.arstechnica.net/wp-content/uploads/2024/03/eternal6-800×514.jpg”></img><figcaption>
<p><a data-height=

Last week, the 2004 cult classic Eternal Sunshine of the Spotless Mind marked its 20th anniversary, prompting many people to revisit the surreal sci-fi psychological drama about two ex-lovers who erase their memories of each other—only to find themselves falling in love all over again. Eternal Sunshine was a box office success and earned almost universal praise upon its release. It’s still a critical favorite today and remains one of star Jim Carrey’s most powerful and emotionally resonant dramatic roles. What better time for a rewatch and in-depth discussion of the film’s themes of memory, personal identity, love, and loss?

(Spoilers for the 2004 film below.)

Director Michel Gondry and co-writer Pierre Bismuth first came up with the concept for the film in 1998, based on a conversation Bismuth had with a female friend who, when he asked, said she would absolutely erase her boyfriend from her memory if she could. They brought on Charlie Kaufman to write the script, and the three men went on to win an Oscar for Best Original Screenplay for their efforts. The title alludes to a 1717 poem by Alexander Pope, “Eloisa to Abelard,” based on the tragic love between medieval philosopher Peter Abelard and Héloïse d’Argenteuil and their differing perspectives on what happened between them when they exchanged letters later in life. These are the most relevant lines:

Of all affliction taught a lover yet,

‘Tis sure the hardest science to forget!

…

How happy is the blameless vestal’s lot!

The world forgetting, by the world forgot.

Eternal sunshine of the spotless mind!

Carrey plays Joel, a shy introvert who falls in love with the extroverted free spirit Clementine (Kate Winslet). The film opens with the couple estranged and Joel discovering that Clementine has erased all her memories of him, thanks to the proprietary technology of a company called Lacuna. Joel decides to do the same, and much of the film unfolds backward in time in a nonlinear narrative as Joel (while dreaming) relives his memories of their relationship in reverse. Those memories dissolve as he recalls each one, even though at one point, he changes his mind and tries unsuccessfully to stop the process.

The twist: Joel ends up meeting Clementine all over again on that beach in Montauk, and they are just as drawn to each other as before. When they learn—thanks to the machinations of a vengeful Lacuna employee—what happened between them the first time around, they almost separate again. But Joel convinces Clementine to take another chance, believing their relationship to be worth any future pain.

Enlarge / Joel (Jim Carrey) and Clementine (Kate Winslet) meet-cute on the LIRR to Montauk.

Much has been written over the last two decades about the scientific basis for the film, particularly the technology used to erase Joel’s and Clementine’s respective memories. The underlying neuroscience involves what’s known as memory reconsolidation. The brain is constantly processing memories, including associated emotions, both within the hippocampus and across the rest of the brain (system consolidation). Research into reconsolidation of memories emerged in the 2000s, in which past memories (usually traumatic ones) are recalled with the intent of altering them, since memories are unstable during the recall process. For example, in the case of severe PTSD, administering Beta blockers can decouple intense feelings of fear from traumatic memories while leaving those memories intact.

Like all good science fiction, Eternal Sunshine takes that grain of actual science and extends it in thought-provoking ways. In the film, so-called “problem memories” can be recalled individually while the patient is in a dream state and erased completely—uncomfortable feelings and all—as if they were computer files. Any neuroscientist will tell you this is not how memory works. What remains most interesting about Eternal Sunshine‘s premise is its thematic exploration of the persistence and vital importance of human memory.

So we thought it would be intriguing to mark the film’s 20th anniversary by exploring those ideas through the lens of philosophy with the guidance of Johns Hopkins University philosopher Jenann Ismael. Ismael specializes in probing questions of physics, metaphysics, cognition, and theory of mind. Her many publications include The Situated Self (2009), How Physics Makes Us Free (2016), and, most recently, Time: A Very Short Introduction (2021).

Eternal Sunshine of the Spotless Mind and the philosophy of self, identity, and memory Read More »

Dogs’ brain activity shows they recognize the names of objects

Behavioral science, Biology, Dogs, Science / Rejus Almole / March 23, 2024

Enlarge / Wired for science!

Boglárka Morvai

Needle, a cheerful miniature schnauzer I had as a kid, turned into a ball of unspeakable noise and fury each time she saw a dog called Puma. She hated Puma so much she would go ballistic, barking and growling. Merely whispering the name “Puma” set off the same reaction, as though the sound of it and the idea of the dog it represented were clearly connected deep in Needle’s mind.

A connection between a word and a mental representation of its meaning is called “referential understanding,” and for a very long time, we believed dogs lacked this ability. Now, a study published by a team of Hungarian researchers indicates we might have been wrong.

Practice makes perfect

The idea that dogs couldn’t form associations with language in a referential manner grew out of behavioral studies in which dogs were asked to do a selective fetching task. The canines had a few objects placed in front of them (like a toy or a bone) and then had to fetch the one specifically named by their owner.

“In laboratory conditions, the dogs performed at random, fetching whatever they could grab first, even though their owners claimed they knew the names of the objects,” said Marianna Boros, a researcher at Neuroethology of Communication Lab at Eötvös Loránd University in Budapest, Hungary. “But the problem is when the dogs are not trained for the task, there are hundreds of things that can disturb them. They can be more interested in one specific toy, they may be bored, or they may not understand the task. So many distractions.”

To get around the issue of distractions, her team checked to see if the dogs could understand words passively using EEG brain monitoring. In humans, the EEG reading that is considered a telltale sign of semantic reasoning is the N400 effect.

“The work on the N400 was first published in 1981, and hundreds of studies replicated it since then with different stimuli. Typically, you show images of objects to the subject and say matching or mismatching names. When you measure EEG brain activity, you will see it looks different in match and mismatch scenarios,” explained Lilla Magyari, also a scientist at Neuroethology of Communication Lab and co-author of the study. (It’s called the N400 effect because the peak of this difference appears around 400 milliseconds after an object is presented, Magyari explained.)

The only change the team made to adapt a standard N400 test to dogs was switching the order of stimuli—the words were uttered first, and the matching or mismatching objects were shown second. “Because when they hear the word which activates mental representation of the object, they are expecting to see it. The sound made them more attentive,” said Magyari.

Timing is everything

In the experiment, the dogs started out lying on a mat with EEG gear on their heads in a room with an experimenter or the owner of a different dog. The owner of the dog being tested was separated by a glass pane with controllable opaqueness. “It was important because EEG studies [can] very precisely time the moment of presentation of your stimulus,” said Boros.

Sentences spoken by the owners that would get the dogs’ attention—things like “Kun-kun, look! The ball!”—were recorded and played to each dog through a loudspeaker. Then, 2,000 milliseconds after each dog heard the sentence, the pane would turn transparent, and the owner would appear holding a matching or mismatching toy. “Each test lasted for as long as the dog was happy to participate. The moment it started to get up or look away, we just stopped the test, and the dog could leave the mat and we just finished by playing sessions. It was all super dog-friendly,” Boros said.

Dogs’ brain activity shows they recognize the names of objects Read More »

Rocket Report: Starship could fly again in May; Ariane 6 coming together

ariane 6, astrobotic, china, european space agency, falcon 9, launch, moon, rocket lab, rocket report, Science, soyuz, Space, spacex, starship / Rejus Almole / March 23, 2024

Eating their lunch —

“I think we’re really going to focus on getting reentry right.”

Stephen Clark – Mar 22, 2024 11: 00 am UTC

Nine kerosene-fueled Rutherford engines power Rocket Lab's Electron launch vehicle off the pad at Wallops Island, Virginia, early Thursday. — Enlarge / Nine kerosene-fueled Rutherford engines power Rocket Lab’s Electron launch vehicle off the pad at Wallops Island, Virginia, early Thursday.

Welcome to Edition 6.36 of the Rocket Report! SpaceX wants to launch the next Starship test flight as soon as early May, the company’s president and chief operating officer said this week. The third Starship test flight last week went well enough that the Federal Aviation Administration—yes, the FAA, the target of many SpaceX fans’ frustrations—anticipates a simpler investigation and launch licensing process than SpaceX went through before its previous Starship flights. However, it looks like we’ll have to wait a little longer for Starship to start launching real satellites.

As always, we welcome reader submissions, and if you don’t want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets, as well as a quick look ahead at the next three launches on the calendar.

Starship could threaten small launch providers. Officials from several companies operating or developing small satellite launch vehicles are worried that SpaceX’s giant Starship rocket could have a big impact on their marketability, Space News reports. Starship’s ability to haul more than 100 metric tons of payload mass into low-Earth orbit will be attractive not just for customers with heavy satellites but also for those with smaller spacecraft. Aggregating numerous smallsats on Starship will mean lower prices than dedicated small satellite launch companies can offer and could encourage customers to build larger satellites with cheaper parts, further eroding business opportunities for small launch providers.

Well, yeah … SpaceX’s dedicated rideshare missions are already reshaping the small satellite launch market. The price per kilogram of payload on a Falcon 9 rocket launching a Transporter mission is less than the price per unit on a smaller rocket, like Rocket Lab’s Electron, Firefly’s Alpha, or Europe’s Vega. Companies operating only in the smallsat launch market tout the benefits of their services, often pointing to their ability to deliver payloads into bespoke orbits, rather than dropping off bunches of satellites into more standardized orbits. But the introduction of Orbital Transfer Vehicles for last-mile delivery services has made SpaceX’s Transporter missions, and potentially Starship rideshares, more attractive. “With Starship, OTVs can become the best option for smallsats,” said Marino Fragnito, senior vice president and head of the Vega business unit at Arianespace. If Starship is able to achieve the very low per-kilogram launch prices proposed for it, “then it will be difficult for small launch vehicles,” Fragnito said.

Rocket Lab launches again from Virginia. Rocket Lab’s fourth launch from Wallops Island, Virginia, and the company’s first there in nine months, took off early Thursday with a classified payload for the National Reconnaissance Office, the US government’s spy satellite agency, Space News reports. A two-stage Electron rocket placed the NRO’s payload into low-Earth orbit, and officials declared it a successful mission. The NRO did not disclose any details about the payload, but in a post-launch statement, the agency suggested the mission was conducting technology demonstrations of some kind. “The knowledge gained from this research will advance innovation and enable the development of critical new technology,” said Chris Scolose, director of the NRO.

A steady customer for Rocket Lab … The National Reconnaissance Office has become a regular customer of Rocket Lab. The NRO has historically launched larger spacecraft, such as massive bus-sized spy satellites, but like the Space Force, is beginning to launch larger numbers of small satellites. This mission, designated NROL-123 by the NRO, was the fifth and last mission under a Rapid Acquisition of a Small Rocket (RASR) contract between NRO and Rocket Lab, dating back to 2020. It was also Rocket Lab’s second launch in nine days, following an Electron flight last week from its primary base in New Zealand. Overall, it was the 46th launch of a light-class Electron rocket since it debuted in 2017. Rocket Lab is building a launch pad for its next-generation Neutron rocket at Wallops. (submitted by EllPeaTea)

The easiest way to keep up with Eric Berger’s space reporting is to sign up for his newsletter, we’ll collect his stories in your inbox.

Night flight for Astrobotic’s Xodiac. The Xodiac rocket, a small terrestrial vertical takeoff and vertical landing technology testbed, made its first night flight, Astrobotic says in a statement. The liquid-fueled Xodiac is designed for vertical hops and can host prototype sensors and other payloads, particularly instruments in development to assist in precision landings on other worlds. This first tethered night flight of Xodiac in Mojave, California, was in preparation for upcoming flight testing with the NASA TechLeap Prize’s Nighttime Precision Landing Challenge. These flights will begin in April, allowing NASA to test the ability of sensors to map a landing field designed to simulate the Moon’s surface in near-total darkness.

Building on the legacy of Masten … Xodiac has completed more than 160 successful flights, dating back to the vehicle’s original owner, Masten Space Systems. Masten filed for bankruptcy in 2022, and the company was acquired by Astrobotic a couple of months later. Astrobotic’s primary business area is in developing and flying robotic Moon landers, so it has a keen interest in mastering automated landing and navigation technologies like those it is testing with NASA on Xodiac. David Masten, founder of Masten Space Systems, is now chief engineer for Astrobotic’s propulsion and test department. “The teams will demonstrate their systems over the LSPG (Lunar Surface Proving Ground) at night to simulate landing on the Moon during the lunar night or in shadowed craters.” (submitted by Ken the Bin)

Rocket Report: Starship could fly again in May; Ariane 6 coming together Read More »

More than half of chickenpox diagnoses are wrong, study finds

CDC, chickenpox, diagnostic, laboratory testing, Science, symptoms / Rejus Almole / March 23, 2024

coin flip —

Vaccination has dramatically reduced cases, making clinical diagnoses tricky.

Beth Mole – Mar 21, 2024 11: 23 pm UTC

Thanks to the vaccination program that began in 1995, chickenpox is now relatively rare. Cases of the miserable, itchy condition have fallen more than 97 percent. But, while children have largely put the oatmeal baths and oven mitts behind them, doctors have apparently let their diagnostic skills get a little crusty.

According to a study published Thursday, public health researchers in Minnesota found that 55 percent of people diagnosed with chickenpox based on their symptoms were actually negative for the varicella-zoster virus, the virus that causes chickenpox. The study noted that the people were all diagnosed in person by health care providers in medical facilities. But, instead of chickenpox, lab testing showed that some of the patients were actually infected with an enterovirus, which can cause a rash, or the herpes simplex virus 1, which causes cold sores.

The study, published in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, supports expanding laboratory testing for suspected chickenpox cases in the state’s program and highlights that diagnoses based on symptoms are “unreliable.”

For one thing, doctors simply see far fewer chickenpox cases these days because of the protection from vaccines. While chickenpox cases in the US previously reached 4 million each year, with 10,500 to 13,500 hospitalizations and 100 to 150 deaths, there are now fewer than 150,000 cases,1,400 hospitalizations, and 30 deaths each year, the CDC reports. Vaccination is more than 90 percent effective at preventing the disease. In the rare cases where a vaccinated person contracts chickenpox, the muted rashes are challenging to identify by eye. But even in unvaccinated children, chickenpox can be tricky to pick out; it can easily be confused with measles, insect bites, enterovirus, skin infections such as scabies and impetigo, herpes viruses, and hand, foot, and mouth disease.

Since 2016, the Minnesota Department of Health has been working to expand laboratory testing, including outreach to health care providers and the public on the importance of testing to confirm suspected chickenpox cases.

Between 2016 and 2023, 208 people who were diagnosed with chickenpox in person at a medical facility submitted specimens for testing to the state health department. Only 93 of the 208 (45 percent) were positive for the virus. The vaccination status was known for 203 of the people—100 were vaccinated, 103 were not. Of the vaccinated people tested, only 22 (22 percent) turned out to have chickenpox, while 68 (66 percent) of the unvaccinated people had it, reflecting the efficacy of vaccination.

In a larger group of 420 people, which included people who were self-diagnosed, the accuracy rate was unsurprisingly lower. Of the 420 suspected chickenpox cases, only 157 (37 percent) were positive for the varicella-zoster virus. Of the remaining 263 people, 47 were positive for enterovirus, 20 were positive for herpes simplex virus 1, 0 were positive for herpes simplex virus 2 (genital herpes), two people had indeterminate test results, and 194 were negative for all four viruses tested.

The authors highlight that the findings are significant because people suspected of having chickenpox are recommended to stay home from school and work longer than people with other viral infections. More testing can ensure appropriate clinical management.

More than half of chickenpox diagnoses are wrong, study finds Read More »

SpaceX’s workhorse launch pad now has the accoutrements for astronauts

crs-30, dragon, falcon 9, international space station, NASA, Science, slc-40, Space, spacex / Rejus Almole / March 23, 2024

Enlarge / A Falcon 9 rocket lifts off Thursday from Cape Canaveral, Florida.

Upgrades at SpaceX’s most-used launch pad in Florida got a trial run Thursday with the liftoff of a Falcon 9 rocket with a Dragon cargo ship heading for the International Space Station.

SpaceX’s Cargo Dragon spacecraft launched at 4: 55 pm EDT (20: 55 UTC) Thursday from Space Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station in Florida. This mission, known as CRS-30, is SpaceX’s 30th resupply mission to the space station since 2012.

The automated Dragon supply ship took off on top of a Falcon 9 rocket, heading for a monthlong stay at the International Space Station, where it will deliver more than 6,000 pounds of hardware, fresh food, and experiments for the lab’s seven-person crew.

In the last few months, SpaceX has outfitted the launch pad with the equipment necessary to support launches of human spaceflight missions on the Crew Dragon spacecraft. The Cargo Dragon capsule is the same size and shape as SpaceX’s Crew Dragon, but it’s filled with cargo racks and storage platforms rather than seats and cockpit displays.

This week, SpaceX technicians used the newly installed launch tower and crew access arm at SLC-40 to load time-sensitive experiments and supplies into the Cargo Dragon capsule atop the Falcon 9 rocket.

“CRS-30 will be our first Dragon to launch from Pad 40 since we put that brand-new crew tower in place,” said Sarah Walker, SpaceX’s director of Dragon mission management, in a prelaunch press conference.

Building new capability

Starting last year, construction crews at Cape Canaveral erected segments of a more than 200-foot-tall metal lattice tower at SLC-40, right next to the starting blocks for SpaceX’s Falcon 9 rocket. Before then, SLC-40 was based on a “clean pad” architecture, without any structures to service or access Falcon 9 rockets while they were vertical on the pad.

In November, contractors raised the crew access arm to an attach point near the top of the tower. This walkway will allow astronauts to crawl into the Crew Dragon spacecraft during a launch countdown. It also provides access to the hatch on the Cargo Dragon spacecraft for final cargo loading.

Earlier this year, SpaceX tested an escape chute at SLC-40 that would be used in an emergency to help astronauts and ground crews quickly get away from the pad. The chute is similar in function to slide-wire baskets in use for decades at LC-39A, but instead of riding a basket from the top of the tower, personnel escaping a pad emergency would slide down a chute to carry them several hundred feet from the rocket.

SpaceX employees tested the pad escape chute last month at SLC-40. Gwynne Shotwell, SpaceX’s president and chief operating officer, took the ride down the chute. “Astronaut and personnel safety is SpaceX’s highest priority, which is why I had to personally test the new slide,” she posted on X, alongside a wink emoji.

Teams test the new emergency chutes from the pad 40 crew tower in Florida pic.twitter.com/rWVj7zaHp0

— SpaceX (@SpaceX) March 19, 2024

“The team took commercially available off the shelf technology and applied it to the crew tower,” Kiko Dontchev, SpaceX’s vice president of launch, wrote on X. “You are trained on it the same way you are trained on using an emergency exit door on airplane. Only takes a couple of quick physical actions to deploy the slide and anyone can effectively do it.”

As more people travel to space, particularly on larger vehicles like SpaceX’s Starship, simplifying safety systems will be important.

“This system will help us scale to bigger towers and spaceships (think 100 people on Starship),” Dontchev wrote.

SpaceX and its contractors completed all of this work as Falcon 9s fired off SLC-40 every few days with Starlink satellites and other missions.

For the last four years, all of SpaceX’s crew and cargo launches to the space station have departed from Launch Complex 39A (LC-39A) at NASA’s Kennedy Space Center, a few miles up the coast from SLC-40. In 2018 and 2019, SpaceX outfitted LC-39A for Cargo Dragon and Crew Dragon missions ahead of the company’s first human spaceflight mission in 2020.

Walker said the new infrastructure added at SLC-40 is “nearly functionally identical” to the equipment for crew missions at LC-39A. The primary differences are the means of pad escape—the chute instead of slide-wire baskets—and a more robust elevator in the tower at SLC-40.

Previously, SpaceX used both SLC-40 and LC-39A for launches of its now-retired first-generation Dragon cargo capsules, which had their final supplies loaded before SpaceX raised the rocket vertical for launch. Like regular satellite launches on Falcon 9s, both pads could support the first-generation Dragon cargo missions.

“Thanks to this new state-of-the-art crew tower required for our human spaceflight missions, that late-load cargo operation got a massive upgrade, too,” Walker said. “It is much easier to load a huge complement of time-critical NASA science into our Dragon spacecraft in the flight orientation.”

SpaceX has drastically ramped up its launch cadence since building LC-39A for Dragon missions. The company plans nearly 150 Falcon 9 or Falcon Heavy launches this year. When you’re flying rockets every two or three days, it’s inevitable two missions will end up vying for the same launch slots. Most recently, that happened in February, when a NASA crew mission was ready to launch from LC-39A around the same time as a narrow launch window for Intuitive Machines’ first commercial lunar lander. Both had to go off of LC-39A.

“Historically, Pad 40 has kind of become our high rate pad,” Walker said. “We’ve gotten the time between launches down to just a couple of days.”

LC-39A has seen less use, primarily for Dragon crew and cargo flights, Falcon Heavy missions, and other “uniquely complex” missions like the Intuitive Machines lander, Walker said.

SpaceX’s workhorse launch pad now has the accoutrements for astronauts Read More »

It’s a few years late, but a prototype supersonic airplane has taken flight

boom supersonic, Science, Space / Rejus Almole / March 22, 2024

Flying high —

“This milestone will be invaluable to Boom’s revival of supersonic travel.”

Eric Berger – Mar 22, 2024 9: 44 pm UTC

Enlarge / XB-1 takes off on its inaugural flight.

Boom Supersonic

A prototype jet independently developed by Boom Supersonic made its first flight on Friday, the company said.

The XB-1 vehicle flew from Mojave Air & Space Port in California, reaching an altitude of 7,120 feet (2.2 km) and a maximum speed of 273 mph (439 kph). In a news release, Boom Supersonic said the initial test flight of the XB-1 aircraft met all of its objectives.

“The experience we have gained in reaching this milestone will be invaluable to Boom’s revival of supersonic travel,” said Bill “Doc” Shoemaker, Chief Test Pilot for Boom Supersonic.

The XB-1 aircraft is a demonstrator intended to test materials and the aerodynamics of a larger commercial supersonic aircraft the company is calling Overture.

Boom is one of a handful of companies attempting to revive supersonic commercial air travel since the Concorde’s final flight in 2003. Its planes are intended to carry between 64 and 80 passengers at about twice the speed of conventional commercial jets in service today. Boom says it has received 130 orders and pre-orders from American Airlines, United Airlines, and Japan Airlines for the Overture vehicle, which it plans to deliver later this decade.

A lot of milestones to go

Boom Supersonic was founded a decade ago, in 2014. It rolled out the XB-1 prototype for the first time in October 2020. At the time, the company said it planned to begin a flight test campaign during the third quarter of 2021. It is not clear why Boom missed that timeline by two and a half years.

The company plans to fly the XB-1 to learn the lessons of supersonic flight with a lower-cost vehicle and incorporate these findings into Overture’s final design. There is only so much technology that can be tested on the ground, and in wind tunnels, so the company needs to fly now to mature its design.

After Friday’s flight, the company said the aircraft’s development team will continue to expand the flight envelope to confirm its performance and handling qualities through and beyond Mach 1.

One key element of the Overture aircraft that the XB-1 prototype is not testing is the engines. The XB-1 is powered by three GE J85-15 engines, a turbojet engine that has been in service for several decades. Boom Supersonic is developing a new engine, a medium-bypass turbofan engine Symphony, for the Overture aircraft.

Previously, the company showcased a one-third scale design model of Symphony, but it has not released information about developmental tests of the hardware. The additively manufactured engine is advertised as having 35,000 pounds of thrust.

It’s a few years late, but a prototype supersonic airplane has taken flight Read More »

Report: Superconductivity researcher found to have committed misconduct

Nature, Physics, research fraud, research misconduct, Science, superconductivity / Paul Patrick / March 21, 2024

Definitely not super —

Details of what the University of Rochester investigation found are not available.

John Timmer – Mar 21, 2024 6: 44 pm UTC

Image of a large lawn, with a domed building flanked by trees and flagpoles at its far end. — Enlarge / Rush Rhees Library at the University of Rochester.

We’ve been following the saga of Ranga Dias since he first burst onto the scene with reports of a high-pressure, room-temperature superconductor, published in Nature in 2020. Even as that paper was being retracted due to concerns about the validity of some of its data, Dias published a second paper claiming a similar breakthrough: a superconductor that works at high temperatures but somewhat lower pressures. Shortly afterward, that got retracted as well.

On Wednesday, the University of Rochester, where Dias is based, announced that it had concluded an investigation into Dias and found that he had committed research misconduct. (The outcome was first reported by The Wall Street Journal.)

The outcome is likely to mean the end of Dias’ career, as well as the company he founded to commercialize the supposed breakthroughs. But it’s unlikely we’ll ever see the full details of the investigation’s conclusions.

Questionable research

Dias’ lab was focused on high-pressure superconductivity. At extreme pressures, the orbitals where electrons hang out get distorted, which can alter the chemistry and electronic properties of materials. This can mean the formation of chemical compounds that don’t exist at normal pressures, along with distinct conductivity. In a number of cases, these changes enabled superconductivity at unusually high temperatures, although still well below the freezing point of water.

Dias, however, supposedly found a combination of chemicals that would boost the transition to superconductivity to near room temperature, although only at extreme pressures. While the results were plausible, the details regarding how some of the data was processed to produce one of the paper’s key graphs were lacking, and Dias didn’t provide a clear explanation. Nature eventually pulled the paper, and the University of Rochester initiated investigations (plural!) of his work.

Those investigations cleared Dias of misconduct, and he quickly was back with a report of another high-temperature superconductor, this one forming at less extreme pressures—somewhat surprisingly, published again by Nature. This time, things fell apart much more rapidly, with potential problems quickly becoming apparent, and many of the paper’s authors, not including Dias, called for its retraction.

The University of Rochester started yet another investigation, which is the one that has now concluded that Dias engaged in research misconduct.

The extent of this misconduct, however, might never be revealed. These internal university investigations are generally not made public, even if it might be in the public’s interest to know. The only recent exception is a case where a researcher accused of misconduct sued her university for defamation over the outcome of the investigation. The university submitted its investigation report as evidence, allowing it to become part of the public record.

Behind the scenes

That said, we have learned a fair bit about what has happened inside Dias’ lab, thanks to Nature News, a sister publication of the scientific journal that published both of Dias’ papers. It conducted a tour-de-force of investigative journalism, talking to Dias’ grad students and obtaining the peer review evaluations of Dias’ two papers.

The investigation showed that, for the first paper, Dias simply told his graduate students that the key data came from before he had set up his own lab, which explains why they weren’t aware of it. The students claimed that the ensuing investigations didn’t contact any of them, suggesting they were extremely similar in scope. By contrast, the students claim to have been more aware that the results presented in the second paper didn’t match up with experiments and, in at least one case, suggested Dias clearly misrepresented his lab’s work. (The paper claimed to have synthesized a chemical that the students say was simply purchased from a supplier.)

They were the ones who organized the effort to retract the paper and said that the final investigation actually sought their input.

Meanwhile, on the peer review side, the reporting does not leave Nature looking especially good. Both papers required several rounds of revision and review before being accepted, and even after all this work, most of the reviewers were ambiguous at best about whether the paper should be published. It was an editorial decision to go ahead despite that.

While things seem to have worked out in the end, the major institutions involved here—Nature and the University of Rochester—aren’t coming out of this unscathed. Neither seems to have taken early indications of misconduct as seriously as it should have. As for Dias, the reporting in the Nature News piece should be career-ending. And it’s worth considering that, in the absence of the reporter’s work, the research community would probably remain unaware of most of the details of Dias’ misconduct.

Report: Superconductivity researcher found to have committed misconduct Read More »

This stretchy electronic material hardens upon impact just like “oobleck”

conductive polymers, flexible electronics, kitchen science, materials science, oobleck, Physics, polymers, Science / Paul Patrick / March 21, 2024

a flexible alternative —

Researchers likened material’s structure to a big bowl of spaghetti and meatballs.

Jennifer Ouellette – Mar 21, 2024 5: 13 pm UTC

Enlarge / This flexible and conductive material has “adaptive durability,” meaning it gets stronger when hit.

Yue (Jessica) Wang

Scientists are keen to develop new materials for lightweight, flexible, and affordable wearable electronics so that, one day, dropping our smartphones won’t result in irreparable damage. One team at the University of California, Merced, has made conductive polymer films that actually toughen up in response to impact rather than breaking apart, much like mixing corn starch and water in appropriate amounts produces a slurry that is liquid when stirred slowly but hardens when you punch it (i.e., “oobleck”). They described their work in a talk at this week’s meeting of the American Chemical Society in New Orleans.

“Polymer-based electronics are very promising,” said Di Wu, a postdoc in materials science at UCM. “We want to make the polymer electronics lighter, cheaper, and smarter. [With our] system, [the polymers] can become tougher and stronger when you make a sudden movement, but… flexible when you just do your daily, routine movement. They are not constantly rigid or constantly flexible. They just respond to your body movement.”

As we’ve previously reported, oobleck is simple and easy to make. Mix one part water to two parts corn starch, add a dash of food coloring for fun, and you’ve got oobleck, which behaves as either a liquid or a solid, depending on how much stress is applied. Stir it slowly and steadily and it’s a liquid. Punch it hard and it turns more solid under your fist. It’s a classic example of a non-Newtonian fluid.

In an ideal fluid, the viscosity largely depends on temperature and pressure: Water will continue to flow regardless of other forces acting upon it, such as being stirred or mixed. In a non-Newtonian fluid, the viscosity changes in response to an applied strain or shearing force, thereby straddling the boundary between liquid and solid behavior. Stirring a cup of water produces a shearing force, and the water shears to move out of the way. The viscosity remains unchanged. But for non-Newtonian fluids like oobleck, the viscosity changes when a shearing force is applied.

Ketchup, for instance, is a shear-thickening non-Newtonian fluid, which is one reason smacking the bottom of the bottle doesn’t make the ketchup come out any faster; the application of force increases the viscosity. Yogurt, gravy, mud, and pudding are other examples. And so is oobleck. (The name derives from a 1949 Dr. Seuss children’s book, Bartholomew and the Oobleck.) By contrast, non-drip paint exhibits a “shear-thinning” effect, brushing on easily but becoming more viscous once it’s on the wall. Last year, MIT scientists confirmed that the friction between particles was critical to that liquid-to-solid transition, identifying a tipping point when the friction reached a certain level and the viscosity abruptly increased.

Wu works in the lab of materials scientist Yue (Jessica) Wang, who decided to try to mimic the shear-thickening behavior of oobleck in a polymer material. Flexible polymer electronics are usually made by linking together conjugated conductive polymers, which are long and thin, like spaghetti. But these materials will still break apart in response to particularly large and/or rapid impacts.

So Wu and Wang decided to combine the spaghetti-like polymers with shorter polyaniline molecules and poly(3,4-ethylenedioxythiophene) polystyrene sulfonate, or PEDOT:PSS—four different polymers in all. Two of the four have a positive charge, and two have a negative charge. They used that mixture to make stretchy films and then tested the mechanical properties.

Lo and behold, the films behaved very much like oobleck, deforming and stretching in response to impact rather than breaking apart. Wang likened the structure to a big bowl of spaghetti and meatballs since the positively charged molecules don’t like water and therefore cluster into ball-like microstructures. She and Wu suggest that those microstructures absorb impact energy, flattening without breaking apart. And it doesn’t take much PEDOT:PSS to get this effect: just 10 percent was sufficient.

Further experiments identified an even more effective additive: positively charged 1,3-propanediamine nanoparticles. These particles can weaken the “meatball” polymer interactions just enough so that they can deform even more in response to impacts, while strengthening the interactions between the entangled long spaghetti-like polymers.

The next step is to apply their polymer films to wearable electronics like smartwatch bands and sensors, as well as flexible electronics for monitoring health. Wang’s lab has also experimented with a new version of the material that would be compatible with 3D printing, opening up even more opportunities. “There are a number of potential applications, and we’re excited to see where this new, unconventional property will take us,” said Wang.

This stretchy electronic material hardens upon impact just like “oobleck” Read More »

Lifesaving gene therapy for kids is world’s priciest drug at $4.25M

drug pricing, fda, gene therapy, health, metachromatic leukodystrophy, Orchard, rare genetic conditions, Science / Mike M. / March 20, 2024

promising but pricey —

It’s unclear if government and private insurance plans can cover the costs.

Beth Mole – Mar 20, 2024 8: 53 pm UTC

Enlarge / A mother with her twin 6-year-old boys who have metachromatic leukodystrophy, a genetic disease that leaves them unable to move. Photo taken on September 3, 2004.

In a medical triumph, US Food and Drug Administration on Monday approved a gene therapy that appears to trounce a rare, tragic disease that progressively steals children’s ability to talk, move, and think, leading to a vegetative state and death. For those who begin to slip away in infancy, many die by age 5. But, with the new therapy, 37 children in an initial trial were all still alive at age 6. Most could still talk, walk on their own, and perform normally on IQ tests, which was unseen in untreated children. Some of the earliest children treated have now been followed for up to 12 years—and they continue to do well.

But, the triumph turned bittersweet today, Wednesday, as the company behind the therapy, Lenmeldy, set the price for the US market at $4.25 million, making it the most expensive drug in the world. The price is $310,000 higher than what experts calculated to be the maximum fair price for the lifesaving drug; the nonprofit Institute for Clinical and Economic Review, or ICER, gave a range last October of between $2.29 million to $3.94 million.

The price raises questions about whether state, federal, and private health insurance plans will be able to shoulder the costs. “Unless states have allocated appropriately for it, and looked at the drug pipeline, they may not be prepared for what could be significant cost spikes,” Edwin Park, a research professor at the McCourt School of Public Health at Georgetown University, told CNN.

It’s also unclear whether the drug can reach the children who need it in time. Lenmeldy must be given before symptoms develop or early on in symptom development in children. However, diagnosis of the rare genetic condition can be slow, and many children treated so far were identified because older siblings, now too old for treatment, developed the condition first.

Devastating disease

Stat, for instance, spoke with the mother of an 8-year-old with the condition, who can no longer talk or move, has frequent seizures, and requires a feeding tube and 28 different medications. Meanwhile, her 3-year-old brother, who has the same genetic mutation, is a typical toddler—he was able to get the new treatment when he was six months old. To get it, the family flew him to Milan, Italy, where Lenmeldy was first developed. It was approved for use in Europe in 2021.

The condition Lenmeldy treats is called metachromatic leukodystrophy (MLD), which occurs in about 40 children in the US each year. MLD is caused by a mutation in the gene that codes for the enzyme arylsulfatase A (ARSA). Without this enzyme, the body can’t break down sulfatides, a fatty substance that then builds up to toxic levels in the brain and peripheral nervous system. Sulfatides are essential components of myelin, the fatty insulation on nerve cells critical for quick transmission of electrical impulses. But, too much sulfatides leads to a loss of myelin, which gradually destroys myelin producing cells and leads to nervous system damage.

Lenmeldy prevents that damage by giving the body a working copy of the ARSA gene. In a one-time infusion, patients are given a dose of their own blood stem cells that have been genetically engineered to contain a functional ARSA gene. Patients undergo chemotherapy to clear out their own stem cells from bone marrow so the genetically modified cells can replace them. The engineered stem cells then produce myeloid cells that travel around the body in the blood, producing ARSA enzyme that can halt progression of MLD.

It’s unknown how long the therapy lasts, but it’s clearly buying children time and giving them hope for a full, normal life.

“MLD is a devastating disease that profoundly affects the quality of life of patients and their families,” Nicole Verdun, director of the FDA’s Office of Therapeutic Products, said in a statement. “Advancements in treatment options offer hope for improved outcomes and the potential to positively influence the trajectory of disease progression.”

It “has the potential to stop or slow the progression of this devastating childhood disease with a single treatment, particularly when administered prior to the onset of symptoms,” Bobby Gaspar, CEO of Lenmeldy’s maker, Orchard Therapeutics, said in a statement Wednesday. “We are committed to enabling broad, expedient, and sustainable access to this important therapy for eligible patients with early-onset MLD in the US.”

The company is working on expanding newborn screening to include tests for MLD, to try to find children early, Orchard reported. Still, with such a rare condition, it’s unclear if the pricey drug will be a moneymaker for the company. Stat notes that Orchard has previously abandoned four therapies for other rare genetic conditions because of the difficulty in meeting regulatory standards for essentially custom therapies and questions about whether health plans will pay the steep, multimillion-dollar prices. In April of last year, Belgium, Ireland, and the Netherlands walked away from price negotiations with the company, saying they couldn’t come to an agreement on this “extremely expensive therapy.”

Lifesaving gene therapy for kids is world’s priciest drug at $4.25M Read More »